PULM - Pulmatrix Corp Analyst Consensus Forecast

Corporate company logo of Pulmatrix Inc (PULM)

This chart illustrating the price history of Pulmatrix, Inc. (PULM), where the consensus forecast stands at 9.99, reflects the dynamics of the biopharma business. Pulmatrix, Inc. (PULM) relies on steady demand, although geopolitical tensions and sanctions could disrupt raw material supplies. Component logistics for inhalers are managed via air transport, eliminating delays. However, the lack of commercial products and reliance on loans, coupled with the risk of failed tests, render the asset high-risk.

Pulmatrix - PULM Price Target Chart (period 07/04/2022 - 11/11/2026)
Flagship merchandise of Pulmatrix Corporation

This indicator reflects the aggregated fair value of the asset, making it possible to determine whether a temporary price dip is a market anomaly or a signal to exit. By analyzing the investment community's average benchmark, an investor assesses the growth potential of Pulmatrix, Inc. (PULM), whose unique developments in high-precision inhalation delivery mechanisms for the lungs create a long-term fundamental basis for revising target prices.

Competitors of Pulmatrix, Inc.

HLN: Forecast Levels Chart|Kenvue - Consensus Target|Analyst Consensus Forecast Verona Pharma PLC VRNA|MENS - Price Target Chart|LGND: Price Target Chart|Amneal Pharmaceuticals (AMRX) - Price Target Chart|Consensus Target perrigo.com|Price Target Chart Alvotech SA|Liquidia Corp - Forecast Levels Chart|Analyst Consensus Forecast GLPG|ANIP (ANI Pharmaceuticals Corp) - Fair Value Consensus|Analyst Consensus Forecast MNKD (MannKind Corporation)|Analyst Consensus Forecast amphastar.com AMPH|PCRX - Price Target Chart|Fair Value Consensus SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price Target Chart|Consensus Target Aquestive Corp|SCPH (scPharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Tectonic|Consensus Target TNXP (Tonix Pharmaceuticals Holding Corp.)|SXTC (sxtchina.com) - Fair Value Consensus|Price Target Chart Eupraxia Pharmaceuticals Inc. EPRX|BioHarvest Sciences Inc (BHST) - Average Forecast Price|EXOZ: Consensus Target|Oramed Pharmaceuticals - Analyst Forecast Prices|ENTX: Analyst Consensus Forecast|MindWalk Holdings, Inc. - Fair Value Consensus|ABVC (ABVC BioPharma Inc) - Analyst Consensus Forecast|Average Forecast Price Cumberland Corp CPIX|Price Target Chart Quantum BioPharma Ltd (QNTM)|FGEN (fibrogen.com) - Fair Value Consensus|Price Target Chart Telomir Pharmaceuticals, Inc. TELO|RANI (Rani Therapeutics Holdings) - Forecast Levels Chart|SNYR: Consensus Target|RLYB - Analyst Consensus Forecast|lexariabioscience.com (LEXX) - Price Target Chart|PTHL (Pheton Holdings) - Price Target Chart|Price Target Chart Aptorum Group Ltd|Consensus Target Lyra Therapeutics Inc. (LYRA)|Analyst Consensus Forecast IBO|Analyst Consensus Forecast tnfpharma.com (TNFA)|cbdMD - Consensus Target|Analyst Forecast Prices PRFX (painreform.com)|CYTO - Price Target Chart|Fair Value Consensus LIPO (Lipella Pharmaceuticals Inc)|OPTN: Analyst Consensus Forecast|PIRS - Analyst Median Target|Consensus Target PROC|Broker Consensus Forecast PTPI (petrospharma.com)|Consensus Target QLI (Qilian International Holding)|SLRN (Acelyrin Inc.) - Fair Value Consensus|Analyst Consensus Forecast TFFP (TFF Pharma)